ClinicalTrials.gg
CompletedNCT04818632AZD9833Updated Dec 17, 2024

AZD9833 China PK Study

A Phase 1 interventional study of AZD9833 and AZD9833 in ER+, HER2-, Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 4 sites in China. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing AZD9833 in Breast Neoplasms — 6 open to participants now, 10 under way, 7 of them phase 3. AZD9833 · Breast Neoplasms.

Enrollment
14th of 17
28 · median 150
Started
2021
with 2 others
Phase 1
7 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
15 of 17
AstraZeneca

Among the 17 studies testing AZD9833 in Breast Neoplasms, this one is the 14th largest by enrollment, is one of 3 that started in 2021, is one of 7 in phase 1, and was the 6th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 17 studies testing AZD9833 in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About AZD9833

AZD9833: first FDA approval 2026 (ETCAMAH), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing AZD9833 in Breast Neoplasms, or all of them as a file.
02

Study summary

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Chinese patients with ER Positive, HER2 Negative, Metastatic Breast Cancer

Read the detailed description

This study is designed to investigate and characterize the safety, tolerability and PK of AZD9833 monotherapy (Part A, Part B-cohort 1) or in combination with palbociclib (optional Part B cohort 2) or everolimus (optional Part B cohort 3) and to explore the preliminary anti-tumour activity in Chinese patients

03

Conditions studied

  • ER+, HER2-, Metastatic Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Open-label
  • Phase 1
  • Safety
  • Tolerability
  • Pharmacokinetics
  • ER Positive
  • HER2 Negative
  • Metastatic Breast Cancer
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any menopausal status:

    1. Pre-menopausal women must have commenced treatment with an LHRH agonist at least 4 weeks prior to the start of study intervention and must be willing to continue to receive LHRH agonist therapy for the duration of the study.
    2. defined according to standard criteria in the protocol.
  2. Histological or cytological confirmation of adenocarcinoma of the breast.
  3. Documented positive ER status and negative status of primary or tumour tissue.
  4. performance status 0 to 1.
  5. Metastatic disease and radiological or objective evidence of progression on or after the last systemic therapy prior to the start of study intervention.
  6. At least one lesion as per Version 1.1 that can be accurately assessed at baseline and is suitable for repeated assessment by CT, MRI, or plain X-ray or clinical examination.
  7. Recurrence or progression on at least one line of endocrine therapy in the metastatic disease setting.
  8. For Part A and Part B cohort 1, patients should be eligible for SERD monotherapy treatment.
  9. For Part B Cohort 2, patients should be eligible for SERD treatment and CDK4/6 inhibitors, and prior treatment with CDK4/6 inhibitors is not permitted.
  10. For Part B Cohort 3, patients should be eligible for SERD treatment and mTOR inhibitors, and prior treatment with mTOR inhibitors is not permitted.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with AZD9833.
  2. Presence of life-threatening visceral disease, uncontrolled CNS metastatic disease or life-threatening extensive hepatic involvement.
  3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, or infection requiring intravenous antibiotic therapy, which makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol.
  4. Inadequate bone marrow reserve or organ function.
  5. Any and symptomatic heart disease.
  6. Any concurrent anti-cancer treatment.
  7. nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833 (and palbociclib and everolimus).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    AZD9833 monotherapy dose escalation

    Drug: AZD9833

  • Experimental
    AZD9833 monotherapy dose expansion

    Drug: AZD9833

  • Experimental
    AZD9833 with palbociclib dose expansion

    Drug: AZD9833 with palbociclib

  • Experimental
    AZD9833 with everolimus dose expansion

    Drug: AZD9833 with everolimus

Interventions

  • Part A: AZD9833 monotherapy dose escalation.

  • Part B: AZD9833 monotherapy dose expansion

  • DrugAZD9833 with palbociclib

    Drug pages: AZD9833 · Palbociclib

    Part B: AZD9833 with palbociclib dose expansion

  • DrugAZD9833 with everolimus

    Drug pages: AZD9833 · Everolimus

    Part B: AZD9833 with everolimus dose expansion

06

What researchers measure

Primary outcomes

  1. The number of subjects with dose-limiting toxicity, as defined in the protocol.

    Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria of AZD9833 monotherapy. \[part A only\]

    Time frame: Minimum observation period 28 days on treatment.

  2. The number of subjects with treatment-related adverse events as assessed by CTCAE v5.0.

    Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of subjects with treatment-related adverse events assessed by CTCAE v5.0 of AZD9833 monotherapy.

    Time frame: 6 months after the last patient recruited starts study intervention or 28 days after the final patient discontinues study intervention

  3. Plasma AZD9833 concentrations and derived PK parameters.

    To characterise the single- and multiple-dose PK of AZD9833 monotherapy.

    Time frame: At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks )

Secondary outcomes

  1. The number of subjects with treatment-related adverse events as assessed by CTCAE v5.0.

    Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of subjects with treatment-related adverse events assessed by CTCAE v5.0 of AZD9833 administered in combination with palbociclib or everolimus..

    Time frame: 6 months after the last patient recruited starts study intervention or 28 days after the final patient discontinues study intervention

  2. Plasma AZD9833 concentrations and derived PK parameters (for optional expansion cohorts Part B Cohorts 2 and 3 only). Everolimus (whole blood) concentrations and derived PK parameters (for optional expansion cohort Part B Cohort 3 only).

    To characterise the single- and/or multiple-dose PK of AZD9833 administered in combination with palbociclib, and single- and/or multiple-dose PK of both AZD9833 and everolimus in combination.

    Time frame: At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks )

  3. Objective Response Rate

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: Week 8 and week 16 and week 24 and then every 12 weeks (week 36, 48, 60) until the end of the study (approximately 1 year)

  4. Duration of Response

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: Week 8 and week 16 and week 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year)

  5. Clinical benefit rate at 24 weeks

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: Up to 24 weeks

  6. Percentage Change in Tumour Size

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: Week 8 and week 16 and week 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year)

  7. Progression Free Survival

    Antitumour activity by evaluation of tumour response assessments using Response Evaluation Criteria in Solid Tumours (RECIST 1.1)

    Time frame: From start of treatment to disease progression/latest date of evaluable RECIST assessment (approximate 1 year)

07

Study locations

4 sites
  • Research Site
    Beijing, 100142, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Wuhan, 430022, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Sep 2023, 21 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 21 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2021
First posted
Mar 26, 2021
StartActual
Nov 12, 2021
Primary completionActual
Sep 7, 2023
CompletionActual
Sep 7, 2023
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04818632
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Nov 12, 2021
Primary completion
Sep 7, 2023
Completion
Sep 7, 2023
Last update
Dec 17, 2024

Study contacts

Jiong Wu
principal investigator · Department of Breast Surgery, Fudan University Shanghai Cancer Center
Jian Zhang
principal investigator · Department of Medical Oncology, Fudan University Shanghai Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD9833 · Palbociclib · Everolimus

Start the discussion